Nonetheless, our analysis identified numerous drugs targeting other components of the TPX2/TTK network, including small molecules targeting AURKA, TOP2A, CDK1, ADRM1, TOP1, PSMA7, RRM2, KIF11, CHEK1, CDC7, XPO1, PPAT, PLK4, and BIRC5 (Fig. 8b), suggesting targeting those genes as an alternative therapeutic strategy for CRC. This evidence concerns the gene BIRC5 and colorectal carcinoma.